跳转至内容
Merck
  • Narrative review: furosemide for hypercalcemia: an unproven yet common practice.

Narrative review: furosemide for hypercalcemia: an unproven yet common practice.

Annals of internal medicine (2008-08-20)
Susan B LeGrand, Dona Leskuski, Ivan Zama
摘要

Although primary hyperparathyroidism is the most common cause of hypercalcemia, cancer is the most common cause requiring inpatient intervention. An estimated 10% to 20% of all patients with cancer have hypercalcemia at some point in their disease trajectory, particularly in advanced disease. Aggressive saline hydration and varying doses of furosemide continue to be the standard of care for emergency management. However, a review of the evidence for the use of furosemide in the medical management of hypercalcemia yields only case reports published before the introduction of bisphosphonates, in contrast to multiple randomized, controlled trials supporting the use of bisphosphonates. The use of furosemide in the management of hypercalcemia should no longer be recommended.

材料
货号
品牌
产品描述

Sigma-Aldrich
呋塞米
Supelco
呋塞米, Pharmaceutical Secondary Standard; Certified Reference Material
USP
呋塞米, United States Pharmacopeia (USP) Reference Standard
Supelco
呋塞米 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
呋塞米, European Pharmacopoeia (EP) Reference Standard
呋塞米, European Pharmacopoeia (EP) Reference Standard